Aakash Desai: “Playing Chess With Cancer” in EGFRm NSCLC
Aakash Desai/LinkedIn

Aakash Desai: “Playing Chess With Cancer” in EGFRm NSCLC

Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:

“My 2022 JAMA Oncology essay ‘Avoiding Checkmate’, seems relevant for thinking about EGFR lung cancer.

Post-osimertinib EGFRm NSCLC:

  • Ami-chemo approved (MARIPOSA-2)
  • Dato-DXd (AA)
  • Ivonescimab, OS missed.

How do we plan line 3 at diagnosis?”

Title: Avoiding Checkmate – Playing Chess With Cancer

Author: Aakash Desai

Read the full article.

You can also read:

MARIPOSA: Amivantamab Plus Lazertinib Reduces EGFR/MET Resistance and Extends Second-Line Disease Control in EGFR-Mutated NSCLC

Aakash Desai: "Playing Chess With Cancer" in EGFRm NSCLC